

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron BA.1 and BA.1.1

Juan Manuel Carreño, Hala Alshammary, Johnstone Tcheou, Gagandeep Singh, Ariel Raskin, Hisaaki Kawabata, Levy Sominsky, Jordan Clark, Daniel C. Adelsberg, Dominika Bielak, Ana Silvia Gonzalez-Reiche, Nicholas Dambrauskas, Vladimir Vigdorovich, PSP/PARIS Study Group, Komal Srivastava, D. Noah Sather, Emilia Mia Sordillo, Goran Bajic, Harm van Bakel, Viviana Simon, Florian Krammer


WHO Global Consultation – What recent evidence do we have that omicron is evading immunity and what are the implications?

February 14th, 2022





**Mount
Sinai**

Setup





- Serum samples (from PARIS study)
- Neutralization of B.1.1.529 isolate (R346)
- ELISA against wild type, B.1.351 and B.1.1.529 RBD, NTD and spike

Overall reduction in neutralizing activity





Negative values set to 5 ID_{50}

Convalescent individuals





Negative values set to 5 ID_{50}

2x Pfizer in previously naive individuals





Negative values set to 5 ID_{50}

3x Pfizer in previously naive individuals




Negative values set to 5 ID₅₀

2x Pfizer in previously infected individuals





Negative values set to 5 ID_{50}

Overall comparison of residual titers to BA.1





Negative values set to 5 ID₅₀

RBD binding





Negative values set to 5 AUC

NTD binding




Negative values set to 5 AUC

Spike binding



Negative values set to 5 AUC

The impact of R346K (BA.1 vs BA.1.1)



Negative values set to 5 AUC

Conclusions

- **Neutralizing activity drops sharply**
- **Convalescent individuals are most affected, followed by double vaccinated individuals**
- **Triple vaccinated and convalescent vaccinated individuals have most residual neutralizing activity**
- **This aligns well with clinical observations and vaccine effectiveness data against symptomatic infection**
- **R346K can cause additional drops in neutralizing activity of polyclonal serum**

Acknowledgements



Krammer Laboratory

Fatima Amanat

Juan Manuel Carreño



florian.krammer@mssm.edu

<http://labs.icahn.mssm.edu/krammerlab/>

Twitter: @florian_krammer



Department of Microbiology/
Icahn School of Medicine at Mount Sinai

Peter Palese

Goran Bajic

Ali Ellebedy (Wash U)

Viviana Simon

Personalized Virology Initiative &
PARIS study group

Aubree Gordon

John Kubale

The PARIS and
SPARTA study teams!



CIVICs
Collaborative Influenza
Vaccine Innovation Centers

Ania Wajnberg
(Mount Sinai Hospital)

Carlos Cordon-Cardo
Adolfo Firpo
(Mount Sinai Hospital)

Harm van Bakel
(ISMMS)

Mia Sordillo
David Reich
Judy Aberg
(Mount Sinai Hospital)

Adolfo García-Sastre

Lisa Miorin
Teresa Aydillo

Tom Moran

Katherine Kedzierska (U Melbourne)
Jussi Hepojoki (U Helsinki)
Olli Vapalahti (U Helsinki)